Current Edition

Comirnaty

As rivals eye ‘unjustified royalties,’ Pfizer partner sues to defend COVID-19 shot Comirnaty

Pfizer has already reeled in tens of billions of dollars in sales for its COVID-19 shot Comirnaty. Now, one of the New York pharma’s partners says rival …

Continue Reading →
cancer

Considerations for Clinical Trial Design Involving Radiotherapy

Radiation therapy has been used for many years as an effective form of treatment against many cancer types, yet it remains less well researched and …

Continue Reading →
clinical

Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint

The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost …

Continue Reading →
Aminex

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Polyamine depletion therapy represents a unique cancer immunotherapy approach Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today …

Continue Reading →
designation

Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy Orchard’s fourth Rare Pediatric Disease Designation for autologous ex vivo gene therapy.

Orchard Therapeutics, a leading commercial stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced that the …

Continue Reading →
clinical

Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy – effective against the WHO Critical Priority Carbapenem resistant bacterial pathogens

The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority …

Continue Reading →
clinical

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient …

Continue Reading →
2017

Shield Therapeutics 2017 Loss Widens On Clinical Trials, Higher Costs

Shield Therapeutics PLC on Wednesday reported significantly widened loss for 2017, as it progresses on Feraccru product study and commercialisation. The specialty pharmaceutical firm reported …

Continue Reading →
business

Domain Therapeutics’ innovative business model gains validation through Prexton Therapeutics’ acquisition by Lundbeck for up to $1.1 billion

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech …

Continue Reading →